Lipidio Pharma Menu

Pipeline

lipido pipeline

GDD3898 NONCLINICAL CLINICAL
Original Development Advanced into Phase 2 clinical development safely tested in >100 subjects
Lipidio’s New Indications
Nonalcoholic steatohepatitis (NASH)
Obesity
Prader-Willi Syndrome (PWS)

About GDD3898

GDD3898 is a clinical-stage Phase 2 drug candidate being developed by Lipidio Pharmaceuticals. Lipidio plans to leverage existing efficacy and human safety data for GDD3898 and conduct new clinical studies to strengthen support for its therapeutic potential in multiple indications.